Characteristics and outcomes of elderly patients with Parkinson's disease hospitalized due to COVID‑19‑associated pneumonia

Patients with Parkinson's disease (PD) and coronavirus disease 2019 (COVID-19)-associated pneumonia present, according to the literature, high mortality rates due to the nature of the disease, advanced age, and underlying diseases. Most available studies, however, refer to the first waves of the pandemic. The aim of the present study was to investigate the clinical characteristics and outcomes of elderly patients (≥65 years old) with PD hospitalized with COVID-19-associated pneumonia during the period of prevalence of various severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants, as well as to determine possible prognostic factors for poor outcomes. During the period from February 15, 2021, to July 15, 2022, 1,144 elderly patients with COVID-19 pneumonia were hospitalized. Age, sex, Charlson comorbidity index, vaccination status against SARS-CoV-2, and admission laboratory parameters were recorded for all patients. A total of 36 (3.1%) patients with PD were hospitalized due to COVID-19-associated pneumonia (18 males, 50%). The mean age of the patients was 82.72±8.18 years. In total, 8 patients (22.2%) were hospitalized during the period of alpha variant predominance, 3 patients (8.3%) during the period of delta variant predominance, and 25 patients (69.4%) during the omicron variant predominance period. Of note, 16 patients (44.4%) were vaccinated with at least two doses. In addition, 17 (47.2%) patients succumbed to the disease. Between the patients who survived and those who succumbed, a statistically significant difference was only found in the mean value of albumin (37.48±6.02 vs. 31.97±5.34 g/l, P=0.019). In particular, as shown by receiver operating characteristic curve analysis, albumin exhibited a satisfactory predictive ability for mortality (area under the curve, 0.780; P=0.013) with an albumin value ≤37.7 g/l being able to predict mortality with 85.7% sensitivity and 54.8% specificity. Overall, the findings of the present study indicate that mortality among elderly patients with PD hospitalized with COVID-19-associated pneumonia was high in all phases of the pandemic. A low albumin value, not only as an indicator of the immune status, but also of the nutritional status, is a predictor of adverse outcomes.

[1]  D. Spandidos,et al.  New‑onset non‑motor symptoms in patients with Parkinson's disease and post‑COVID‑19 syndrome: A prospective cross‑sectional study , 2023, Medicine international.

[2]  S. Papageorgiou,et al.  Exploring the Role of ACE2 as a Connecting Link between COVID-19 and Parkinson’s Disease , 2023, Life.

[3]  A. Koyanagi,et al.  Is Dementia Associated with COVID-19 Mortality? A Multicenter Retrospective Cohort Study Conducted in 50 Hospitals in Germany. , 2022, Journal of Alzheimer's disease : JAD.

[4]  D. Spandidos,et al.  Onodera's prognostic nutritional index: Comparison of its role in the severity and outcomes of patients with COVID‑19 during the periods of alpha, delta and omicron variant predominance. , 2022, Experimental and therapeutic medicine.

[5]  Yandeng Li,et al.  Serum albumin, cognitive function, motor impairment, and survival prognosis in Parkinson disease , 2022, Medicine.

[6]  F. Taghizadeh,et al.  The effects of Alzheimer's and Parkinson's disease on 28-day mortality of COVID-19 , 2021, Revue Neurologique.

[7]  M. Etemadifar,et al.  Parkinson's disease patients may have higher rates of Covid-19 mortality in Iran , 2021, Parkinsonism & Related Disorders.

[8]  A. Galanopoulou,et al.  Outcome of Hospitalized Parkinson's Disease Patients with and without COVID‐19 , 2021, Movement disorders clinical practice.

[9]  R. Gold,et al.  Clinical Profiles and Mortality of COVID‐19 Inpatients with Parkinson's Disease in Germany , 2021, Movement disorders : official journal of the Movement Disorder Society.

[10]  A. Kurniawan,et al.  Parkinson's disease may worsen outcomes from coronavirus disease 2019 (COVID-19) pneumonia in hospitalized patients: A systematic review, meta-analysis, and meta-regression , 2021, Parkinsonism & Related Disorders.

[11]  K. Melmed,et al.  A Prospective Study of Neurologic Disorders in Hospitalized Patients With COVID-19 in New York City , 2020, Neurology.

[12]  I. Koralnik,et al.  Frequent neurologic manifestations and encephalopathy‐associated morbidity in Covid‐19 patients , 2020, Annals of clinical and translational neurology.

[13]  A. Padovani,et al.  Lifting the mask on neurological manifestations of COVID-19 , 2020, Nature Reviews Neurology.

[14]  L. Tönges,et al.  Letter to the editor: risk comorbidities of COVID-19 in Parkinson’s disease patients in Germany , 2020, Neurological Research and Practice.

[15]  A. Fasano,et al.  COVID‐19 in Parkinson’s Disease Patients Living in Lombardy, Italy , 2020, Movement disorders : official journal of the Movement Disorder Society.

[16]  L. Romito,et al.  Effects of COVID‐19 on Parkinson's Disease Clinical Features: A Community‐Based Case‐Control Study , 2020, Movement disorders : official journal of the Movement Disorder Society.

[17]  K. Walters,et al.  Factors associated with hospitalisation among people with Parkinson's disease - A systematic review and meta-analysis. , 2020, Parkinsonism & related disorders.

[18]  P. Bugalho,et al.  Motor and non-motor function predictors of mortality in Parkinson’s disease , 2019, Journal of Neural Transmission.

[19]  J. Finsterer,et al.  Cardiac abnormalities in Parkinson’s disease and Parkinsonism , 2018, Journal of Clinical Neuroscience.

[20]  B. Guthrie,et al.  Co-morbidity and polypharmacy in Parkinson’s disease: insights from a large Scottish primary care database , 2017, BMC Neurology.

[21]  A. Lees,et al.  Dementia in Parkinsonism , 2011, Journal of Neural Transmission. Supplementa.